Clinical Meaningfulness of Response to Tanezumab in Patients with Chronic Low Back Pain: Analysis From a 56-Week, Randomized, Placebo- and Tramadol-Controlled, Phase 3 Trial

INTRODUCTION: A recent phase 3, randomized, placebo- and tramadol-controlled trial (56-week treatment/24-week safety follow-up) demonstrated efficacy of tanezumab 10 mg in patients with chronic low back pain (CLBP) and a history of inadequate response to standard-of-care analgesics. Here, we report...

Descripción completa

Detalles Bibliográficos
Autores principales: Markman, John D., Schnitzer, Thomas J., Perrot, Serge, Beydoun, Said R., Ohtori, Seiji, Viktrup, Lars, Yang, Ruoyong, Bramson, Candace, West, Christine R., Verburg, Kenneth M.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer Healthcare 2022
Materias:
Original Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9633876/
https://www.ncbi.nlm.nih.gov/pubmed/35962939
http://dx.doi.org/10.1007/s40122-022-00424-7

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9633876/
https://www.ncbi.nlm.nih.gov/pubmed/35962939
http://dx.doi.org/10.1007/s40122-022-00424-7

Ejemplares similares